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atives. AAbstract The synthesis and pharmacological evaluation of new series of 4-((3-aryl-4,5-dihydroi-
soxazol-5-yl)methoxy)-2H-chromen-2-ones 3a–f prepared by cycloaddition reaction using various
arylnitrile oxides with the suitable 4-(allyloxy)-2H-chromen-2-one 2a are described. The 2-
methyl-2,3-dihydrothieno[3,2-c]chromen-4-one 8 was also synthesized due to chemospeciﬁcity by
the thio-Claisen rearrangement of 4-(allylthio)-2H-chromene-2-thione 7a. We also describe the
new heterocyclic compounds 4-(R-thio)-2H-chromene-2-thiones 7a–d, 4-(2-thioxo-2H-chromen-4-
ylthio) 5 and 4,40-thiobis (2H-chromen-2-one) 6 which were prepared by a classical and PTC alkyl-
ation of 4-mercapto-2H-chromene-2-thione 4 with allylic halides.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
The coumarin skeleton is found in many natural products and
is also used as a synthetic intermediate for the preparation of
numerous heterocyclic compounds, possessing a wide
spectrum of biological activities (Paramjeet et al., 2012;3500279.
hoo.fr (H.B. Jannet).
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rabian Journal of ChemistryMutalik and Phaniband, 2011) such as antibacterial (Olayinka
and Obinna, 2010), antiviral, antitumor (Hua et al., 2008),
anti-HIV and anti-inﬂammatory properties (More and
Mahulikar, 2011). Main representatives of this class are the
4-hydroxy-2H-chromen-2-one and the 4-mercapto-2H-chro-
mene-2-thione, which also have shown good anticoagulant
activity combined with low side effects, little toxicity (Manolov
et al., 2006) and very useful for the synthesis of other coumarin
derivatives. Until now, an enormous number of heterocyclic
compounds with fused isoxazoline and dihydrothiophene have
been excellently reviewed (Desai et al., 2008; Majumdar et al.,
2010). Particularly, isoxazoline is a ﬁve-membered heterocyclic
which is a versatile lead compound for designing potent
bioactive agents (Kaur et al., 2010; Baseer et al., 2012). It ising Saud University.
synthesis, antibacterial and anticoagulant activities of novel
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2 I. Zghab et al.interesting to note from the chemical literature that 2-isoxazo-
line derivatives showed various biological activities such as
anti-stress (Rakesh et al., 2011), antinociceptive (Karthikeyan
et al., 2009), anticonvulsant (Hemlata et al., 2010), analgesic
(Habeeb et al., 2001) and anti-inﬂuenza effects (Kai et al.,
2001). Also they showed a good potency in animal models of
thrombosis (Pinto, 2001) and played a crucial role in the theo-
retical development of heterocyclic chemistry.
The 1,3-dipolar cycloaddition has been the subject of in-
tense research over the last decade, due to its great synthetic
value (Nair and Suja, 2007) and was the most effective process
to the synthesis of ﬁve-membered heterocycles which are difﬁ-
cult to be prepared with other means. Furthermore, it gives ac-
cess to several substances with pronounced biological activities
(Gaonkar et al., 2007; Jadhav, 2010). As a part of our search
for ﬁve-membered heterocyclic compounds, we proposed to
investigate the behavior of the 4-(allyloxy)-2H-chromen-2-
one 2a among other analogs 2b–d, all prepared from the
natural synthon, the 4-hydroxy-2H-chromen-2-one 1 toward
different arylnitrile oxides as a dipole (Pellissier, 2007). The
reaction was regiospeciﬁc and led to a series of new 4-
((3-aryl-4,5-dihydroisoxazol-5-yl)methoxy)-2H-chromen-2-ones
3a–f. Next, the 4-(2-thioxo-2H-chromen-4-ylthio)-2H-chro-
men-2-one 5 and the 4,40-thiobis (2H-chromen-2-one) 6 have
been synthesized from allylic halides and 4-mercapto-2H-chro-
mene-2-thione 4 by the application of the phase-transfer catal-
ysis condition. Similarly, the S-alkylation of 4 under classical
conditions using K2CO3 and acetone was also investigated
for the preparation of new 4-(allylthio)-2H-chromene-2-thi-
ones 7a–d. Following the same way, we have developed the
1,3-cycloaddition between various arylnitrile oxides and 4-
(allylthio)-2H-chromene-2-thione 7a, however this speciﬁc
addition provided, via the Claisen rearrangement, the 2-
methyl-2,3-dihydrothieno[3,2-c]chromen-4-one 8. The evalua-
tion of the anticoagulant and antibacterial activities of all
the synthesized heterocycles has been studied and reported
here.2. Results and discussion
The requisite starting materials for this study, the 4-(allyloxy)-
2H-chromen-2-ones 2a–d, were prepared by a classical alkyl-
ation (Avetisyan and Alvandzhyan, 2006) by condensing the
4-hydroxy-2H-chromen-2-one 1 in equimolar amounts with
different allylic halides in reﬂuxing anhydrous acetone in the
presence of potassium carbonate for 20 h to give a number
of 4-(allyloxy)-2H-chromen-2-ones 2a–d (Scheme 1).
The structures of compounds 2a–d were established on the
basis of their spectroscopic data. Thus, compound 2a (as an
example) was obtained as a white solid, its ES-MS spectrum
gave a pseudo-molecular ion peak [M+ H]+ at m/z 203 which
is consistent with the molecular formula C12H10O3. The
1H
NMR spectrum of compound 2a run at 300 MHz in CDCl3
indicates the presence of characteristic signals of coumarin
skeleton which can be, according to their chemical shifts and
multiplicity, readily assigned to H-3 (dH 5.69, s, 1H), H-7
(dH 7.55, m, 1H), H-5 (dH 7.85, dd, 1H, J= 8.1 Hz,
J= 1.5 Hz) and H-6,8 (dH 7.29, m, 2H). In addition to the
signals corresponding to the protons introduced by 4-hydro-
xy-2H-chromen-2-one, we revealed the appearance of a signal
at dH 4.69 (d, 2H, J= 6 Hz) relative to the protons H-20. ThePlease cite this article in press as: Zghab, I. et al., Regiospeciﬁc
isoxazoline chromene derivatives. Arabian Journal of Chemistrytwo doublet of doublets signal at dH 5.42 (dd, 1H,
J= 10.5 Hz, J= 0.9 Hz) and dH 5.52 (dd, 1H, J= 17.1 Hz,
J= 0.9 Hz) was attribuated to the terminal ethylenic protons
H-40a and H-40b. The multiplet at dH 6.07 (m, 1H) was as-
signed to the ethylenic proton H-30. On the other hand, C-20
(69.8 ppm), C-40 (119.5 ppm), C-30 (130.7 ppm) and aromatic
carbons: C-5, C-6, C-7 and C-8 were readily assigned from
the 13C NMR spectrum.
Encouraged by our results and in conjunction with the
pharmaceutical importance known for fused heterocyclic
incorporating a coumarin moiety, we chose to explore the ter-
minal oleﬁn moiety in order to synthesize new isoxazoline
chromenes. Compound2a was treated according to the 1,3-
dipolar cycloaddition with various arylnitrile oxides as a dipole
(Liu et al., 1980) in reﬂuxing anhydrous toluene for 6 h, that
provided the corresponding heterocyclic compounds 3a–f
(Scheme 1).
Compound 3b was obtained as a white powder. Its positive
ES–MS showed a pseudo-molecular ion peak [M+ H]+ at m/
z 336 compatible with the molecular formula C20H17NO4. The
structure was evidenced by the disappearance in the 1H NMR
spectrum of the signal at dH 5.46 relative to the terminal ethyl-
enic protons, the appearance of a doublet of doublets signal at
dH 3.50 (dd, 2H, J= 16.8 Hz, J= 6.6 Hz) attributable to the
protons H-40 and the presence of a singlet at dH 2.39 (s, 3H)
corresponding to the methyl protons. A characteristic AA0BB0
pattern for aromatic hydrogens was observed in the 1H NMR
spectrum. Examination at 300 MHz offered an excellent reso-
lution with a doublet at dH 7.25 (d, 2H, J= 8.1 Hz, H-30 0,50 0)
and a second doublet at dH 7.60 (d, 2H, J= 8.1 Hz, H-20 0,60 0).
The 13C NMR spectrum conﬁrmed the above spectral data by
the observation of signals at 126.0 (C-10 0), 126.7 (C-20 0,60 0),
129.5 (C-30 0,50 0) and 140.8 (C-400) ppm relative to carbons of
the p-substituted aromatic system. The same spectrum showed
signals at dC 77.4 and 156.2 attributable to the bearing oxygen
carbon C-50 and C-30 of the imine function, respectively. In
addition, a whole set of linkages conﬁrming the molecular
structure of compound 3b was reinforced by the HMBC
spectrum which showed correlations between the proton H-40synthesis, antibacterial and anticoagulant activities of novel
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.10.008
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H-20 0,60 0 and C-10 0, C-30 and C-40 0. Moreover, the regiochemist-
ry was conﬁrmed by the NOE observed between the protons
H-40 and the aromatic protons H-200,60 0.
The regioselectivity of this cycloaddition reaction generally
leads to a mixture of 1,4 and 1,5-regioisomers (Lora´nd et al.,
2009). Although, in this study the novel 1,2,4-isoxazoline
derivatives 3a–f were formed as unique products, indicating
the regiospeciﬁcity of the reaction. Indeed, the non formation
of the other 1,5-regioisomer may be explained by a possible
steric crowding and by electronic factors.
On the other hand, the preparation of the substrates 4-
(allylthio)-2H-chromene-2-thione 7a–d was tested according
to the literature (Majumdar and Ghosh, 2002) by phase-trans-
fer catalyzed alkylation of 4-mercapto-2H-chromene-2-thione
4, prepared according to the previously reported method
(Ibrahim, 2006), with a number of different allylic halides
using tertiary butyl ammonium chloride (TBAC) in aqueous
sodium hydroxide and chloroform. Coincidentally the PTC
did not afford the desired products 7a–d, but provided two
new heterocyclic compounds 4-(2-thioxo-2H-chromen-4-
ylthio)-2H-chromen-2-one 5 and 4,40-thiobis (2H-chromen-2-
one) 6 (Scheme 2).
Compounds 5 and 6 were established on the basis of their
spectroscopic data. Their positive HRMS-ESI showed pseu-
do-molecular ion peaks [M+ Na]+ at m/z 360.9954 and at
m/z 345.0189, respectively, which were consistent with the
molecular formulas C18H10O3NaS2 and C18H10O4NaS, respec-
tively. Then the structural assignment of the products 5 and 6
was made on the basis of 1H and 13C NMR spectral analysis
and by comparison of their spectroscopic data with those
reported for related systems. In particular, the 1H NMR spec-
trum of compound 5 exhibited two singlets at dH 6.39 (s, 1H)
and at dH 7.24 (s, 1H) attributable to two ethylenic protons H-
3 and H-30, respectively. In addition, four doublet of doublets
was observed at dH 7.42 (dd, 1H, J= 8.1 Hz, J= 1.6 Hz), dH
7.54 (dd, 1H, J= 8.1 Hz, J= 1.6 Hz), dH 7.69 (dd, 1H,
J= 8.4 Hz, J= 1.5 Hz) and dH 7.82 (dd, 1H, J= 8.4 Hz,O
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Scheme 2 Synthesis of derivatives 7a–d and products 5, 6.
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H-80, H-5 and H-50, respectively. Also we observed four multi-
plets at dH 7.36 (m, 1H), dH 7.38 (m, 1H), dH 7.65 (m, 1H) and
dH 7.69 (m, 1H) assignable to the aromatic protons H-6, H-60,
H-7 and H-70, respectively.
Compared to that of compound 5, the 1H NMR spectrum
of 6 indicates the presence of characteristic signals of coumarin
skeleton which can be, according to their chemical shifts and
multiplicity, readily assigned to H-3 (6.42 ppm, s, 1H), H-6
(7.34 ppm, m, 1H), H-8 (7.40 ppm, dd, 1H, J= 8.4 Hz,
J= 1.5 Hz), H-7 (7.64 ppm, m, 1H) and H-5 (7.80 ppm, dd,
1H, J= 7.8 Hz, J= 1.5 Hz). A complete 13C assignment of
compounds 5 and 6 was evidenced by the persistence of each
of them similarly signals at dC 158.4 relative to the lactone car-
bonyl and the presence of a signal at dC 194.1 attributed to the
thione of compound 5.
To solve the problem unambiguously caused by dimeriza-
tion, it sufﬁced to condense compound 4 with various allylic
halides, in reﬂuxing anhydrous chloroform in the presence of
potassium carbonate (Majumdar et al., 1992) for 24 h provid-
ing the corresponding heterocyclic compounds 7a–d
(Scheme 2). Whole of the combined spectral data conclusively
agrees with the conﬁrmed structures, compared to those of
compounds 2a–d. However, the relative deshielding of the aro-
matic protons in compounds 7a–d is due to the sulfur atom.
Furthermore, this reaction exhibits two sites; a novel termi-
nal oleﬁn system and the thione function as dipolarophiles,
which normally react in 1,3-dipolar cycloaddition reactions
with arylnitrile oxides. We performed this reaction as shown
in Scheme 3.
This reaction did not give the suitable heterocycles but it
has led, via the Claisen rearrangement (Majumdar and Biswas,
2004), to the formation of the 2-methyl-2,3-dihydrothieno[3,2-
c]chromen-4-one 8. The structure 8 was ascertained from its
spectroscopic data. For example, its 1H NMR spectrum
showed a singlet at dH 1.45 (s, 3H) corresponding to methyl
protons, two doublet of doublets at dH 2.97 (dd, 1H,
J= 16.5 Hz, J= 5.4 Hz) and dH 3.42 (dd, 1H, J= 16.5 Hz,
J= 8.7 Hz) attributable to the diastereotopic protons H-3a
and H-3b, respectively, together with a multiplet signal at dH
4.09 (m, 1H) relative to the proton H-2. The 13C NMR spec-
trum of 8 was also a good support for the proposed structure
which exhibited characteristic signals at dC 23.0, 41.4 and 45.7
corresponding to carbon of the methyl group, C-3 and C-2 of
dihydrothiophene moiety, respectively. Also, the quaternary
carbons (C-3a, and C-9b) appeared at dC 116.7 and 153.1.
We have noticed that the arylnitrile oxides reacted neither
with the terminal ethylenic system nor with the thioneO
S
S
R1
R2
7a
N
Ar
Cl
OH
Toluene, (Et)3N
Δ
O
S
CH3
Ha
Hb
O
Ar
N C S
9a-c
9a-c Ar= p-MePh, p-ClPh,
p-NO2Ph
8
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4 I. Zghab et al.function. Hence, the products 8 and 9a–c were obtained as a
result from a mono-condensation of the dipole on the thione
function of the dipolarophile leading to an unstable spiro-com-
pound which underwent an intramolecular rearrangement to
give exclusively the 2-methyl-2,3-dihydrothiophene fused cou-
marin 8 and the aryl isothiocyanates 9a–c (Elhazazi et al.,
2003).
3. Antibacterial activity
Compounds 3a–f were screened for their antibacterial activity
against two Gram-negative bacteria (Escherichia coli and Pseu-
domonas aeruginosa) and two other Gram-positive bacteria
(Staphylococcus aureus and Enterococcus faecalis). The ob-
tained data revealed that most of the compounds showed mod-
erate to excellent activities against the used microorganisms
(Table 1). Gentamicin was used as a reference drug for the
determination of antibacterial activities. DMSO was used as
a blank exhibited no activity against any of the used strains.
It has been observed that some of the compounds exhibited
interesting antibacterial activities. Indeed, compounds 3a, 3b
and 3d showed effective activity against P. aeruginosa
(MIC = 0.03 mg/mL) compared to that of Gentamicin
(MIC = 0.5 mg/mL). Moreover, compound 3f with the pyrrol
system showed a good activity against E. faecalis
(MIC = 0.31 mg/mL) but a little less active than the remaining
compounds. An increase of afﬁnity of compound 3a against S.
aureus, E. faecalis and E. coli (MIC = 0.62 mg/mL) was ob-
served. This result could be due to the absence of any substitu-
ent in the aryl system of compound 3a. A further drop in
activity of compound 3d against S. aureus, E. faecalis and
E. coli (MIC = 1.25 mg/mL) as well as of compound 3f
against E. coli and P. aeruginosa (MIC = 1.25 mg/mL) was
noted. Compound 3e displayed poor activity against both
Gram-positive and Gram-negative bacteria.
4. Anticoagulant activity
The in vitro anticoagulant activity of the synthesized 4-((3-aryl-
4,5-dihydroisoxazol-5-yl)methoxy)-2H-chromen-2-one deriva-
tives 3a–f was assessed by measuring the activated partial
thromboplastin time and was compared to that of 4-hydro-
xy-2H-chromen-2-one 1 which has been used as starting mate-
rial for their synthesis and as positive control. The results are
shown in Table 2. All compounds 3a–f had profound anticoag-
ulant activities as indicated by the signiﬁcant prolongation of
aPTT in a concentration-dependent manner.
As shown in Table 2, the aPTT assay indicated that com-
pounds 3a and 3f exhibited the highest anticoagulant activity.
The potency of the compound 3e was similar to that of couma-
rin-derived product 3d whereas 3c and 3b had much lower anti-
coagulant activities.
Introduction of 3-aryl-4,5-dihydroisoxazol-5-yl (3a) and 3-
(1H-pyrrol-2-yl)-4,5-dihydroisoxazole scaffolds (3f) at the
coumarin C-4 position resulted in signiﬁcantly increased anti-
coagulant potency, which suggested that those chemical
groups are responsible for the improvement of their anticoag-
ulant activities. Compounds 3b and 3c both bearing an alkyl-
ated aryl moiety were shown to be the less active tested
derivatives.Please cite this article in press as: Zghab, I. et al., Regiospeciﬁc
isoxazoline chromene derivatives. Arabian Journal of Chemistry5. Conclusion
In conclusion, we have successfully achieved in this work two
important aspects: the methodology by a classical alkylation
for the 4-O- and 4-S-allylic chromene derivatives 2a–d and
7a–d, respectively; and a practical method for the synthesis
of new isoxazoline chromene derivatives 3a–f and 2-methyl-
2,3-dihydrothieno[3,2-c]chromen-4-one 8 via 1,3-dipolar cyclo-
addition involving arylnitrile oxides. These cycloadditions
display appreciable regiospeciﬁcity and chemospeciﬁcity, giv-
ing the products in good yields. It has also been observed that
most of the prepared isoxazolines 3a–f exhibited interesting
antibacterial activity against some Gram negative and Gram
positive strains. Indeed, the compounds 3a, 3b and 3d showed
effective activity (MIC = 0.03 mg/mL) toward P. aeruginosa
compared to that of Gentamicin (MIC = 0.5 mg/mL) used
as a positive control. The biological evaluation showed that
isoxazolines 3a–f had profound anticoagulant potency. While
introducing 3-aryl-4,5-dihydroisoxazol-5-yl (3a) and 3-(1H-
pyrrol-2-yl)-4,5-dihydroisoxazole scaffolds (3f) at the couma-
rin C-4 position resulted in signiﬁcantly increased anticoagu-
lant effect.
6. Experimental section
Melting points were taken on a Bu¨chi-510 capillary melting
point apparatus. 1H (300 MHz) and 13C (75 MHz) NMR
spectra were recorded with AC-300 Bruker spectrometers.
Mass spectra were obtained with Micromass LCT (ESI tech-
nique, positive mode) spectrometer. HRMS spectra were ac-
quired with an ESI–TOF (LCT Premier XE, Waters) using
the reﬂectron mode in the positive ion mode. Leucine-
enkephalin peptide was employed as the LockSpray lock-
mass. Commercial TLC plates (Silica gel 60, F254, SDS) were
used to monitor the progress of the reaction. Column chro-
matography was performed with silica gel 60 (particle size
40–63 lm, SDS).
6.1. General procedure for the synthesis of compounds 2a–d
Different allylic halides (1 mmol) were slowly added under
stirring to a mixture of (100 mL) of anhydrous acetone,
(1.62 g, 1 mmol) of compound 1 and (0.11 mmol) of anhy-
drous potassium carbonate. The mixture was heated for 20 h
on a water bath, the solvent was distilled off, and the residue
was treated with ice water. After 12 h, the precipitate was ﬁl-
tered off and crystallization from (CHCl3/EP, 2:8) the fur-
nished pure 2a–d.
6.1.1. 4-(allyloxy)-2H-chromen-2-one (2a)
White solid, yield 97%, 1.57 g, mp 124–125 C (CHCl3/EP,
2:8). 1H NMR (300 MHz, CDCl3): dH 4.69 (d, 2H,
J= 6 Hz, H-20), 5.42 (dd, 1H, J= 10.5 Hz, J= 0.9 Hz, H-
40a), 5.52 (dd, 1H, J= 17.1 Hz, J= 0.9 Hz, H-40b), 5.69 (s,
1H, H-3), 6.07 (m, 1H, H-30), 7.29 (m, 2H, H-6,8), 7.55 (m,
1H, H-7), 7.85 (dd, 1H, J= 8.1 Hz, J= 1.5 Hz, H-5). 13C
NMR (75 MHz, CDCl3): dC 69.8 (C-20), 90.9 (C-3), 115.7 (C-
4a), 116.7 (C-8), 119.5 (C-40), 123.0 (C-6), 123.8 (C-5), 130.7
(C-30), 132.4 (C-7), 153.3 (C-8a), 162.8 (C-2), 165.2 (C-4).
ES-MS m/z 203 [M+H]+.synthesis, antibacterial and anticoagulant activities of novel
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Table 2 Anticoagulant activity of compounds 3a–f deter-
mined by measuring the activated partial thromboplastin time
(s).
C (lg/mL) 1 3a 3b 3c 3d 3e 3f
0 31.6 31.6 31.6 31.6 31.6 31.6 31.6
500 47.2 57.9 48.5 49.4 44.6 45.7 57.6
750 77.4 72.5 55.3 54.7 63 68.8 72.1
1000 103.6 111 95.8 91 101.5 102.8 104.5
Table 1 Antibacterial activity, represented by as MIC (mg/mL), of compounds 3a–f.
Compound
(mg/mL)
Staphylococcus aureus
(ATCC25923)
Enterococcus faecalis
(ATCC 29212)
Escherichia coli
(ATCC 25922)
Pseudomonas aeruginosa
(ATCC 27950)
3a 0.62 0.62 0.62 0.03
3b 2.5 2.5 5 0.03
3c 1.25 2.5 5 1.25
3d 1.25 1.25 1.25 0.03
3e 2.5 5 >10 5
3f >10 0.31 1.25 1.25
Gentamicin 0.0156 0.0078 0.0039 0.5
Regiospeciﬁc synthesis, antibacterial and anticoagulant activities of novel isoxazoline chromene derivatives 56.1.2. 4-(3-methylbut-2-enyloxy)-2H-chromen-2-one (2b)
White solid, yield 11%, 178 mg, mp 144–145 C (CHCl3/EP,
2:8). 1H NMR (300 MHz, CDCl3): dH 1.76 (s, 3H, CH3),
1.83 (s, 3H, CH3), 4.67 (d, 2H, J= 6.6 Hz, H-2
0), 5.50 (m,
1H, H-30), 5.67 (s, 1H, H-3), 7.28 (m, 2H, H-6,8), 7.53 (m,
1H, H-7), 7.83 (dd, 1H, J= 7.8 Hz, J= 1.5 Hz, H-5). 13C
NMR (75 MHz, CDCl3): dC 25.0 (CH3), 32.5 (CH3), 72.8 (C-
20), 97.3 (C-3), 122.5 (C-4a), 123.4 (C-8), 123.9 (C-30), 129.8
(C-6), 130.5 (C-5), 138.9 (C-7), 147.2 (C-40), 160.0 (C-8a),
169.8 (C-2), 172.2 (C-4). ES-MS m/z 231 [M+H]+.
6.1.3. 4-(Cinnamyloxy)-2H-chromen-2-one (2c)
White powder, yield 40%, 557 mg, mp 164–165 C (CHCl3/
EP, 2:8). 1H NMR (300 MHz, CDCl3): dH 4.88 (d, 2H,
J= 6.9 Hz, H-20), 5.80 (s, 1H, H-3), 6.46 (m, 1H, H-30), 6.85
(d, 1H, J= 15.6 Hz, H-40), 7.29–7.43 (m, 5H, Harom), 7.50
(m, 2H, H-6,8), 7.59 (m, 1H, H-7), 7.91 (dd, 1H, J= 6.9 Hz,
J= 1.5 Hz, H-5). 13C NMR (75 MHz, CDCl3): dC 69.9 (C-
20), 90.94 (C-3), 115.7 (C-4a), 116.8 (C-8), 121.4 (C-6), 123.1
(C-5), 123.9 (C-80), 126.7 (C-60,100), 128.5 (C-70,90), 129.2 (C-
30), 132.4 (C-7), 135.3 (C-40), 135.6 (C-50), 153.3 (C-8a), 162.9
(C-2), 165.3 (C-4). ES-MS m/z 279 [M+H]+.
6.1.4. 4-(2-Bromobenzyloxy)-2H-chromen-2-one (2d)
White cottony, yield 80%, 1.28 g, mp 178–179 C (CHCl3/EP,
2:8). 1H NMR (300 MHz, CDCl3): dH 5.30 (s, 2H, H-20), 5.82
(s, 1H, H-3), 7.29–7.44 (m, 4H, H-6,60,8,80), 7.56 (m, 2H, H-
7,70), 7.66 (dd, 1H, J= 8.1 Hz, J= 1.2 Hz, H-50), 7.90 (dd,
1H, J= 7.8 Hz, J= 1.5 Hz, H-5). 13C NMR (75 MHz,
CDCl3): dC 70.5 (C-20), 91.45 (C-3), 115.5 (C-4a), 116.8 (C-8),
123.0 (C-6), 123.1 (C-40), 124.0 (C-5), 130.3 (C-70), 130.5 (C-
80), 130.6 (C-60), 132.5 (C-7), 133.1 (C-50), 133.7 (C-30), 153.3
(C-8a), 162.7 (C-2), 165.0 (C-4). ES-MS m/z 331 [M+H]+.
6.2. Preparation of compounds 3a–f
The arylnitrile oxides were prepared according to the general
procedure, generated from aldoximes by halogenationPlease cite this article in press as: Zghab, I. et al., Regiospeciﬁc
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lissier, 2007). To a mixture of 4-(allyloxy)-2H-chromen-2-one
2a (0.2 g, 0.98 mmol) in reﬂuxing toluene, the appropriate aryl-
nitrile oxide (1.5 equiv.) in the presence of triethylamine
(1.5 equiv.) was added and the mixture was reﬂuxed for 6–
20 h. The residue obtained after removing the solvent in vacuo,
was chromatographed on silica gel, employing (EP/AcOEt,
6:4) as eluent. Crystallization from (CH2Cl2/EP, 2:8) gives
3a–f.
6.2.1. 4-((3-Phenyl-4,5-dihydroisoxazol-5-yl)methoxy)-2H-
chromen-2-one (3a)
White solid, yield 28%, 55 mg, mp 169–171 C (CH2Cl2/EP,
2:8). 1H NMR (300 MHz, CDCl3): dH 3.40 (dd, 1H,
J= 16.8 Hz, J= 6.6 Hz, H-40a), 3.66 (dd , 1H, J= 16.8 Hz,
J= 11.1 Hz, H-40b), 4.29 (m, 2H, H-60), 5.25 (m, 1H, H-50),
5.70 (s, 1H, H-3), 7.15 (m, 1H, H-6), 7.28 (m, 1H, H-8),
7.43–7.47 (m, 3H, H-3’’,4’’,5’’), 7.52 (m, 1H, H-7), 7.67 (dd,
1H, J= 7.8 Hz, J= 1.2 Hz, H-5), 7.73 (m, 2H, H-2’’,6’’).
13C NMR (75 MHz, CDCl3): dC 37.3 (C-40), 69.9 (C-60), 78.8
(C-50), 90.9 (C-3), 115.2 (C-4a), 116.7 (C-8), 123.0 (C-5),
123.9 (C-6), 126.8 (C-2’’,6’’), 128.8 (C-3’’,5’’), 128.9 (C-1’’),
130.5 (C-4’’), 132.5 (C-7), 153.0 (C-8a), 156.2 (C-30), 162.5
(C-2), 165.2 (C-4). ES–MS m/z 322 [M+ H]+.
6.2.2. 4-((3-p-Tolyl-4,5-dihydroisoxazol-5-yl)methoxy)-2H-
chromen-2-one (3b)
White solid, yield 52%, 130 mg, mp 109–110 C (CH2Cl2/EP,
2:8). 1H NMR (300 MHz, CDCl3): dH 2.39 (s, 3H, CH3),
3.36 (dd, 1H, J= 16.5 Hz, J= 6.3 Hz, H-40a), 3.50 (dd, 1H,
J= 16.5 Hz, J= 10.8 Hz, H-40b), 4.25 (m, 2H, H-60), 5.21
(m, 1H, H-50), 5.68 (s, 1H, H-3), 7.14 (m, 1H, H-6), 7.25 (d,
2H, J= 8.1 Hz, H-3’’,5’’), 7.27 (d, 1H, J= 7.8 Hz, H-8),
7.51 (m, 1H, Hz, H-7), 7.60 (d, 2H, J= 8.1 Hz, H-2’’,6’’),
7.67 (dd, 1H, J= 7.8 Hz, J= 1.2 Hz, H-5). 13C NMR
(75 MHz, CDCl3): dC 21.4 (CH3), 37.4 (C-40), 70.0 (C-60),
77.4 (C-50), 90.8 (C-3), 115.2 (C-4a), 116.7 (C-8), 123.0 (C-5),
123.9 (C-6), 126.0 (C-1’’), 126.7 (C-2’’,6’’), 129.5 (C-3’’,5’’),
132.5 (C-7), 140.8 (C-4’’), 153.2 (C-8a), 156.2 (C-30), 162.5
(C-2), 165.2 (C-4). ES-MS m/z 336 [M+H]+.
6.2.3. 4-((3-(4-Ethylphenyl)-4,5-dihydroisoxazol-5-
yl)methoxy)-2H-chromen-2-one (3c)
White solid, yield 48%, 94.5 mg, mp 116–117 C (CH2Cl2/EP,
2:8). 1H NMR (300 MHz, CDCl3): dH 1.28 (t, 3H, J= 7.5 Hz,
CH3), 2.71 (q, 2H, CH2), 3.39 (dd, 1H, J= 16.5 Hz,
J= 6.3 Hz, H-40a), 3.51 (dd , 1H, J= 16.5 Hz, J= 10.8 Hz,
H-40b), 4.29 (m, 2H, H-60), 5.23 (m, 1H, H-50), 5.70 (s, 1H,synthesis, antibacterial and anticoagulant activities of novel
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.10.008
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(m, 1H, H-7), 7.65 (d, 2H, J= 8.4 Hz, H-2’’,6’’), 7.70 (dd,
1H, J= 7.8 Hz, J= 1.5 Hz, H-5). 13C NMR (75 MHz,
CDCl3): dC 15.3 (CH3), 28.8 (CH2), 37.5 (C-40), 69.9 (C-60),
77.2 (C-50), 90.8 (C-3), 115.2 (C-4a), 116.7 (C-8), 123.0 (C-5),
123.9 (C-6), 126.2 (C-1’’), 126.8 (C-2’’,6’’), 128.4 (C-3’’,5’’),
132.6 (C-7), 147.1 (C-4’’), 153.2 (C-8a), 156.2 (C-30), 162.6
(C-2), 165.2 (C-4). ES-MS m/z 350 [M+ H]+.
6.2.4. 4-((3-(4-Chlorophenyl)-4,5-dihydroisoxazol-5-
yl)methoxy)-2H-chromen-2-one (3d)
White solid, yield 72%, 144 mg, mp 142–144 C (CH2Cl2/EP,
2:8). 1H NMR (300 MHz, CDCl3): dH 3.35 (dd, 1H,
J= 16.5 Hz, J= 6.6 Hz, H-40a), 3.60 (dd, 1H, J= 16.5 Hz,
J= 11.1 Hz, H-40b), 4.27 (m, 2H, H-60), 5.23 (m, 1H, H-50),
5.69 (s, 1H, H-3), 7.14 (m, 1H, H-6), 7.27 (d, 1H,
J= 8.4 Hz, H-8), 7.40 (d, 2H, J= 8.4 Hz, H-3’’,5’’), 7.51
(m, 1H, H-7), 7.62–7.66 (m, 3H, H-5,2’’,6’’). 13C NMR
(75 MHz, CDCl3): dC 37.1 (C-40), 69.9 (C-60), 77.9 (C-50),
90.9 (C-3), 115.2 (C-4a), 116.7 (C-8), 122.8 (C-5), 123.9 (C-
6), 127.4 (C-1’’), 128.0 (C-2’’,6’’), 129.1 (C-3’’,5’’), 132.6 (C-
7), 136.5 (C-4’’), 153.2 (C-8a), 155.4 (C-30), 162.5 (C-2),
165.1 (C-4). ES-MS m/z 356 [M+ H]+.
6.2.5. 4-((3-(4-Nitrophenyl)-4,5-dihydroisoxazol-5-
yl)methoxy)-2H-chromen-2-one (3e)
White solid, yield 10%, 30 mg, mp 152–153 C (CH2Cl2/EP,
2:8). 1H NMR (300 MHz, CDCl3): dH 3.52 (m, 2H, H-40),
4.35 (m, 2H, H-60), 5.36 (m, 1H, H-50), 5.75 (s, 1H, H-3),
7.17 (m, 1H, H-6), 7.30 (m, 1H, H-8), 7.54 (m, 1H, H-7),
7.65 (m, 1H, H-5), 7.91 (d, 2H, J= 8.4 Hz, H-3’’,5’’), 8.32
(d, 2H, J= 8.1 Hz, H-2’’,6’’). 13C NMR (75 MHz, CDCl3):
dC 36.8 (C-40), 69.8 (C-60), 78.8 (C-50), 91.3 (C-3), 115.1 (C-
4a), 116.9 (C-8), 122.7 (C-5), 123.9 (C-6), 124.2 (C-3’’,5’’),
127.6 (C-2’’,6’’), 132.7 (C-7), 134.9 (C-1’’), 148.7 (C-4’’),
153.2 (C-8a), 154.8 (C-30), 162.6 (C-2), 165.1 (C-4). ES-MS
m/z 367 [M+ H]+.
6.2.6. 4-((3-(1H-pyrrol-2-yl)-4,5-dihydroisoxazol-5-
yl)methoxy)-2H-chromen-2-one (3f)
White solid, yield 35%, 86 mg, mp 164–165 C (CH2Cl2/EP,
2:8). 1H NMR (300 MHz, CDCl3): dH 3.50 (dd, 1H,
J= 16.5 Hz, J= 6.3 Hz, H-40a), 3.69 (dd, 1H, J= 16.5 Hz,
J= 10.8 Hz, H-40b), 4.29 (m, 2H, H-60), 5.25 (m, 1H, H-50),
5.57 (s, 1H, H-3), 7.12 (m, 1H, H-8), 7.20 (m, 1H, H-6), 7.29
(m, 2H, H-2’’,3’’), 7.46 (d, 1H, J= 6.3 Hz, H-4’’), 7.53 (m,
1H, H-7), 7.70 (dd, 1H, J= 7.8 Hz, J= 1.8 Hz, H-5). 13C
NMR (75 MHz, CDCl3): dC 38.1 (C-40), 69.8 (C-60), 78.1 (C-
50), 90.9 (C-3), 115.2 (C-4a), 116.7 (C-8), 122.9 (C-5), 123.0
(C-6), 124.0 (C-4’’), 127.4 (C-2’’,3’’), 128.8 (C-1’’), 132.6 (C-
7), 152.0 (C-8a), 153.2 (C-30), 162.5 (C-2), 165.2 (C-4). ES-
MS m/z 311 [M+ H]+.
6.3. Synthesis of 4-mercapto-2H-chromene-2-thione 4
4-Hydroxycoumarin (1.62 g, 1 mmol) and Lawesson0s reagent
(4.04 g, 1 mmol) in anhydrous toluene (90 mL) were heated un-
der reﬂux for 4 h. The dark brown solution was evaporated un-
der reduced pressure to give a dark red solid, which was
ﬁltered, washed with ethanol and dried to yield pure 4.Please cite this article in press as: Zghab, I. et al., Regiospeciﬁc
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Red solid, yield 77%, 1.2 g, mp 217–219 C (ethanol). 1H
NMR (300 MHz, CDCl3): dH 7.16 (s, 1H, H-3), 7.37 (t, 1H,
J= 7.5 Hz, H-6), 7.52 (d, 1H, J= 8.4 Hz, H-8), 7.69 (t, 1H,
J= 8.4 Hz, H-7), 7.79 (d, 1H, J= 7.8 Hz, H-5). 13C NMR
(75 MHz, CDCl3): dC 117.5 (C-3), 119.1 (C-8), 124.8 (C-7),
125.9 (C-5), 131.2 (C-4a), 133.5 (C-6), 140.6 (C-8a), 155.7
(C-4), 193.9 (C-2). ESI-HRMS: m/z [M–H] calcd for
(C9H5OS2)
: 192.9782; found: 192.9777.
6.4. Preparation of compounds 5 and 6
To a mixture of 4-mercapto-2H-chromene-2-thione 4 (0.5 g,
0.22 mmol) and allylic bromide (1.2 equiv.) in chloroform
(20 mL) was added a solution of TBAC (0.1 mol) in 1%
aq. NaOH (10 mL) and the mixture was stirred for 6 h. It
was then diluted with water (20 mL) and extracted with
CH2Cl2 (2 · 20 mL). The combined extracts were treated with
2 N HCl (2 · 10 mL), then washed with water (2 · 10 mL)
and dried over Na2SO4. The resulting residue was puriﬁed
by chromatography on silica gel using CH2Cl2 as eluent.
Crystallization from (CH2Cl2/EP, 2:8) gives compounds 5
and 6.
6.4.1. 4-(2-Thioxo-2H-chromen-4-ylthio)-2H-chromen-2-one
(5)
Yellow powder, yield 17%, 85 mg, mp 224–226 C (CH2Cl2/
EP, 2:8). 1H NMR (300 MHz, CDCl3): dH 6.39 (s, 1H, H-3),
7.24 (s, 1H, H-30), 7.36 (m, 1H, H-6), 7.38 (m, 1H, H-60),
7.42 (dd, 1H, J= 8.1 Hz, J= 1.6 Hz, H-8), 7.54 (dd, 1H,
J= 8.1 Hz, J= 1.6 Hz, H-80), 7.65 (m, 1H, H-7), 7.69 (m,
1H, H-70), 7.69 (dd, 1H, J= 8.4 Hz, J= 1.5 Hz, H-5), 7.82
(dd, 1H, J= 8.4 Hz, J= 1.5 Hz, H-50). 13C NMR (75 MHz,
CDCl3): dC 117.4 (C-80), 117.5 (C-4a), 117.7 (C-3), 119.2 (C-
40a), 124.8 (C-5), 124.9 (C-50), 125.0 (C-60), 125.9 (C-6), 133.3
(C-7,70), 133.5 (C-80), 139.9 (C-40), 148.7 (C-4), 152.9 (C-8a),
155.8 (C-80a), 158.4 (C-2), 194.1 (C-20). ESI-HRMS: m/z
[M + Na]+ calcd for (C18H10O3NaS2)
+: 360.9969; found:
360.9954.
6.4.2. 4,40-thiobis (2H-chromen-2-one) (6)
Beige solid, yield 29%, 143 mg, mp 156–158 C (CH2Cl2/EP,
2:8). 1H NMR (300 MHz, CDCl3): dH 6.42 (s, 1H, H-3),
7.34 (m, 1H, H-6), 7.40 (dd, 1H, J= 8.4 Hz, J= 1.5 Hz,
H-8), 7.64 (m, 1H, H-7), 7.80 (dd, 1H, J= 7.8 Hz,
J= 1.5 Hz, H-5). 13C NMR (75 MHz, CDCl3): dC 117.5
(C-4a), 117.7 (C-8), 118.7 (C-3), 125.1 (C-5,6), 133.4 (C-7),
148.4 (C-4), 153.1 (C-8a), 158.4 (C-2). ESI-HRMS: m/z
[M + Na]+ calcd for (C18H10O4NaS)
+: 345.0198; found:
345.0189.
6.5. General procedure for the synthesis of 7a–d
An excess of different allylic halides was added to a solution of
compound 4 (0.5 g, 0.25 mmol) and (0.11 mmol) of anhydrous
potassium carbonate in anhydrous CHCl3 (30 mL). The mix-
ture was reﬂuxed for 24 h. The residue obtained after removing
the solvent in vacuo, was chromatographed on silica gel,
employing (EP/CH2Cl2, 1:1) as eluent. Crystallization from
(CH2Cl2/EP, 2:8) gives 7a–d.synthesis, antibacterial and anticoagulant activities of novel
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.10.008
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Orange cottony, yield 64%, 317 mg, mp 131–132 C (CH2Cl2/
EP, 2:8). 1H NMR (300 MHz, CDCl3): dH 3.75 (d, 2H,
J= 7.5 Hz, H-20), 5.37 (dd, 1H, J= 12 Hz, J= 1.2 Hz, H-
40a), 5.48 (dd, 1H, J= 16.8 Hz, J= 1.2 Hz, H-40b), 5.95 (m,
1H, H-30), 7.12 (s, 1H, H-3), 7.33 (m, 1H, H-6), 7.46 (dd, 1H,
J= 8.4 Hz, J= 1.2 Hz, H-8), 7.60 (m, 1H, H-7), 7.76 (dd,
1H, J= 8.1 Hz, J= 1.5 Hz, H-5). 13C NMR (75 MHz,
CDCl3): dC 34.1 (C-20),117.5 (C-3), 119.8 (C-4a), 120.7 (C-8),
121.8 (C-40), 124.0 (C-6), 125.5 (C-5), 130.3 (C-30), 132.9 (C-
7), 150.1 (C-4) 154.9 (C-8a), 194.4 (C-2). ESI-HRMS: m/z
[M + H]+ calcd for (C12H11OS2)
+: 235.0251; found: 235.0242.
6.5.2. 4-(3-Methylbut-2-enylthio)-2H-chromene-2-thione (7b)
Orange solid, yield 14%, 42 mg, mp 144–145 C (CH2Cl2/EP,
2:8). 1H NMR (300 MHz, CDCl3): dH 1.71 (s, 3H, CH3),
1.80 (s, 3H, CH3), 3.75 (d, 2H, J= 7.5 Hz, H-2
0), 5.29 (m,
1H, H-30), 7.00 (s, 1H, H-3), 7.30 (m, 2H, H-6,8), 7.50 (m,
1H, H-7), 7.67 (dd, 1H, J= 8.1 Hz, J= 1.5 Hz, H-5). 13C
NMR (75 MHz, CDCl3): dC 18.9 (CH3), 24.5 (CH3), 29.3 (C-
20), 107.7 (C-3), 115.0 (C-4a), 120.6 (C-8), 121.0 (C-40), 122.0
(C-6), 127.5 (C-5), 129.4 (C-30), 132.8 (C-7), 152.1 (C-4)
154.0 (C-8a), 196.4 (C-2). ES-MS m/z 265 [M+H]+.
6.5.3. 4-(cinnamylthio)-2H-chromene-2-thione (7c)
Orange solid, yield 15%, 43 mg, mp 183–184 C (CH2Cl2/EP,
2:8). 1H NMR (300 MHz, CDCl3): dH 3.92 (d, 2H,
J= 6.9 Hz, H-20), 6.30 (m, 1H, H-30), 6.79 (m, 1H, H-40),
7.21 (s, 1H, H-3), 7.28–7.49 (m, 7H, H-6,8,arom), 7.46 (m,
1H, H-7), 7.75 (m, 1H, H-5). 13C NMR (75 MHz, CDCl3):
dC 33.6 (C-20), 117.2 (C-3), 119.4 (C-4a), 120.5 (C-8), 121.4
(C-6), 123.7 (C-5), 123.8 (C-50), 125.2 (C-80), 126.6 (C-60,100),
128.3 (C-70,90), 128.7 (C-30), 132.6 (C-7), 135.8 (C-40), 149.9
(C-4), 154.5 (C-8a), 194 (C-2). ESI-HRMS: m/z [M + H]+
calcd for (C18H15OS2)
+: 311.0564; found: 311.0572.
6.5.4. 4-(2-bromobenzylthio)-2H-chromene-2-thione (7d)
Orange solid, yield 30%, 60 mg, mp 194–195 C (CH2Cl2/EP,
2:8). 1H NMR (300 MHz, CDCl3): dH 5.38 (s, 2H, H-20),
7.20 (s, 1H, H-3), 7.49–7.69 (m, 4H, H-6,60,8,80), 7.73 (m,
2H, H-7,70), 7.78 (m, 2H, H-5,50). 13C NMR (75 MHz,
CDCl3): dC 38.2 (C-20), 117.5 (C-3), 119.4 (C-4a), 121.5 (C-
8), 122.0 (C-6), 122.7 (C-40), 124.0 (C-5), 127.8 (C-70), 129.0
(C-80), 129.6 (C-60), 129.8 (C-7), 131.6 (C-50), 135.8 (C-30),
149.9 (C-4), 154.5 (C-8a), 194.0 (C-2). ES-MS m/z 364
[M+ H]+.
6.6. Preparation of compound 8
To compound 7a (0.1 g, 0.23 mmol) in reﬂuxing anhydrous
toluene, the appropriate arylnitrile oxide (1.5 equiv.) in the
presence of triethylamine (1.5 equiv.) was added and the mix-
ture was reﬂuxed for 8 h. The solvent was then removed under
reduced pressure. The resulting residue was puriﬁed by silica
gel column chromatography (EP/AcOEt, 8:2) to give com-
pound 8.
6.6.1. 2-Methyl-2,3-dihydrothieno[3,2-c]chromen-4-one (8)
Orange solid, yield 24%, 20 mg, mp 159–160 C (EP/AcOEt,
8:2). 1H NMR (300 MHz, CDCl3): dH 1.45 (s, 3H, CH3),Please cite this article in press as: Zghab, I. et al., Regiospeciﬁc
isoxazoline chromene derivatives. Arabian Journal of Chemistry2.97 (dd, 1H, J= 16.5 Hz, J= 5.4 Hz, H-3a), 3.42 (dd, 1H,
J= 16.5 Hz, J= 8.7 Hz, H-3b), 4.09 (m, 1H, H-2), 7.15–
7.31 (m, 3H, H-6,8,9), 7.43 (m, 1H, H-7). 13C NMR
(75 MHz, CDCl3): dC 23.0 (CH3), 41.4 (C-3), 45.7 (C-2),
116.7 (C-3a), 116.9 (C-6), 119.3 (C-9a), 124.2 (C-8), 125.8
(C-9), 131.7 (C-7), 153.1 (C -9b), 157.4 (C-5a), 157.8 (C-4).
ES-MS m/z 219 [M+ H]+.
6.7. Biological methods
6.7.1. Antibacterial activity
The MIC was deﬁned as the lowest concentration able to inhi-
bit any visible bacterial growth. MIC values were determined
by a microtitre plate dilution method (Jabrane et al., 2010) dis-
solving the sample in 10% DMSO solution. Sterile 10%
DMSO solution (100 lL) was pipetted into all wells of the
microtitre plate before transferring 100 lL of stock solution
to the microplate. Serial dilutions were made to obtain concen-
tration ranging from 10 to 0.03 mg/mL. Finally, 50 lL of 106
colony forming units (cfu/mL) (according to Mc Farland tur-
bidity standards) of standard microorganism suspensions was
inoculated onto microplates and incubated at 37 C for 24 h.
At the end of incubation period, the plates were evaluated
for the presence or absence of growth. Gentamicin was used
as antibacterial positive control. MIC values were determined
as the lowest concentration of the sample at which the absence
of growth was recorded. All the samples were screened three
times against each microorganism.
6.7.2. Anticoagulant activity
Activated partial thromboplastin time (aPTT) was performed
using Platelin LS reagent (Trinity Biotech PLC, Cowicklow,
Ireland) on a STAR analyzer (Diagnostica Stago, Asnie`res,
France), according to the manufacture protocol (Mansour
et al., 2010). Coagulation test was performed on 4-((3-aryl-
4,5-dihydroisoxazol-5-yl)methoxy)-2H-chromen-2-ones deriv-
atives 3a–f samples at various concentrations diluted in a pool
of frozen normal plasma. 4-hydroxy-2H-chromen-2-one 1 was
used as reference.
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